Century Therapeutics, Inc. financial data

Symbol
IPSC on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
25 N 38 Th Street, 11 Th Floor, Philadelphia, PA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 5, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.08K % +15%
Debt-to-equity 94 % +38.5%
Return On Equity -66.6 % -35.1%
Return On Assets -34.3 % -16.9%
Operating Margin -5.39K % +1.53%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 85M shares +42.1%
Common Stock, Shares, Outstanding 84.6M shares +42.1%
Entity Public Float 132M USD -64.2%
Common Stock, Value, Issued 9K USD +50%
Weighted Average Number of Shares Outstanding, Basic 84.7M shares +42.5%
Weighted Average Number of Shares Outstanding, Diluted 84.7M shares +42.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 2.69M USD +7.92%
General and Administrative Expense 34M USD -1.07%
Operating Income (Loss) -145M USD -6.26%
Nonoperating Income (Expense) 13.9M USD +1.63%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -131M USD -3.62%
Income Tax Expense (Benefit) -854K USD -131%
Net Income (Loss) Attributable to Parent -130M USD -0.73%
Earnings Per Share, Basic -1.86 USD/shares +14.7%
Earnings Per Share, Diluted -0.37 USD/shares +32.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 52.6M USD -4.91%
Other Assets, Current 1.57M USD
Assets, Current 206M USD +18.6%
Property, Plant and Equipment, Net 65.3M USD -20.4%
Operating Lease, Right-of-Use Asset 28.8M USD +17.4%
Intangible Assets, Net (Excluding Goodwill) 33.8M USD
Goodwill 4.73M USD
Assets 389M USD -2.25%
Accounts Payable, Current 2.6M USD -56.2%
Employee-related Liabilities, Current 6.22M USD +11.7%
Accrued Liabilities, Current 721K USD
Liabilities, Current 19.8M USD -3.01%
Deferred Income Tax Liabilities, Net 3.5M USD
Operating Lease, Liability, Noncurrent 50.8M USD +11.6%
Liabilities 193M USD +8.19%
Accumulated Other Comprehensive Income (Loss), Net of Tax 758K USD
Retained Earnings (Accumulated Deficit) -746M USD -21.1%
Stockholders' Equity Attributable to Parent 196M USD -10.7%
Liabilities and Equity 389M USD -2.25%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -30.2M USD -3.52%
Net Cash Provided by (Used in) Financing Activities 18.2M USD +3961%
Net Cash Provided by (Used in) Investing Activities 11.5M USD -63.2%
Common Stock, Shares Authorized 300M shares +140%
Common Stock, Shares, Issued 84.8M shares +42.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 55.4M USD -3.24%
Interest Paid, Excluding Capitalized Interest, Operating Activities 345K USD +45%
Deferred Tax Assets, Valuation Allowance 127M USD +62.4%
Deferred Tax Assets, Gross 138M USD +53.6%
Operating Lease, Liability 54.6M USD +14.8%
Depreciation 13.6M USD +15.6%
Payments to Acquire Property, Plant, and Equipment 539K USD -89.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -128M USD -0.93%
Lessee, Operating Lease, Liability, to be Paid 87M USD +1.75%
Property, Plant and Equipment, Gross 98M USD -4.98%
Operating Lease, Liability, Current 3.76M USD +84.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 9.77M USD +14.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.4M USD -70.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure +10.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 28.3M USD -3.62%
Lessee, Operating Lease, Liability, to be Paid, Year Three 9.33M USD +15.9%
Deferred Tax Assets, Operating Loss Carryforwards 31.1M USD -11.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 9.57M USD +16.4%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 10.4M USD -8.06%
Share-based Payment Arrangement, Expense -1.02M USD -132%
Interest Expense 913K USD -29.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%